Corifollitropin alfa for ovarian stimulation in in vitro fertilization: a systematic review and meta-analysis of randomized controlled trials

Corifollitropin alfa is as effective as recombinant follicle-stimulating hormone in terms of live birth rate, on- going pregnancy rate, and clinical pregnancy rate in both normal and poor responders.

0
0

Volume 111, Issue 4, Pages 722–733

Authors:

Mauro Cozzolino, M.D., Amerigo Vitagliano, M.D., Gustavo Nardini Cecchino, M.D., Guido Ambrosini, M.D., Juan Antonio Garcia-Velasco, Ph.D.

Abstract:

Objective

To evaluate the effectiveness of corifollitropin alfa in improving the success of IVF.

Design

Systematic review and meta-analysis.

Setting

Not applicable.

Patient(s)

Infertile women undergoing conventional IVF or intracytoplasmic sperm injection (ICSI).

Intervention(s)

Randomized controlled trials (RCTs) of infertile women undergoing a single IVF/ICSI cycle with either corifollitropin alfa or a conventional ovarian stimulation protocol based on daily injections. The review protocol was registered in PROSPERO before starting the data extraction (CRD42018088605).

Main Outcome Measure(s)

Primary outcomes were live birth rate and/or ongoing pregnancy rate. Clinical pregnancy rate, miscarriage rate, multiple pregnancies, number of oocytes and embryos obtained, cancellation rate, and rate of ovarian hyperstimulation syndrome and ectopic pregnancy were considered as secondary outcomes.

Result(s)

Eight randomized controlled trials were included; 2,345 women were assigned to the intervention group and 1,995 to the control group. The analysis of 4,340 IVF cycles did not reveal any difference in live birth rate and/or ongoing pregnancy rate between groups (risk ratio [RR], 0.92; 95% confidence interval [CI], 0.80–1.05). Similarly, no difference was found in clinical pregnancy rate (RR, 0.96; 95% CI, 0.88–1.05; I2 = 0%), miscarriage rate (RR, 0.94; 95% CI, 0.71–1.25; I2 = 0%), or multiple pregnancy rate (RR, 1.22; 95% CI, 0.99–1.50; I2 = 0%). Also, the rates of cycle cancellation, ovarian hyperstimulation syndrome, and ectopic pregnancy were similar in both groups. Sensitivity and subgroup analyses did not provide statistical changes to pooled results.

Conclusion(s)

Corifollitropin alfa seems to be an alternative for daily recombinant FSH injections in normal and poor responder patients undergoing ovarian stimulation in IVF/ICSI treatment cycles.


Read the full text here.


Medium untitled 1

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.